QGEN
QIAGEN N.V.
Next earnings Aug 3, 2026 (after close) · consensus $0.61 EPS, $539M rev
$39.41
▲ +1.21%$39.41▼ -10.64%
over 1Y
L $32.63EODHDH $55.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.2%
1W+8.6%
1M+9.1%
3M+0.9%
YTD-8.1%
1Y-10.6%
Buy
Conviction
Horizon
Long (>12mo)
Street · 23 analysts
Buy
High-margin molecular-diagnostics franchise with recovering profitability — net income rebounded sharply on a 62% gross margin.
Revenue $2.09B · FY2025
The read
Quality fundamentals and an attractive price line up (~87% below fair value) — the rarer case where both the business and the entry look good.
QIAGEN is a high-quality molecular-diagnostics and sample-technology company with a razor-and-blade consumables model that produces a 62.2% gross margin. FY2025 marked a strong profitability recovery: revenue grew 5.7% to $2.09B while net income jumped to $425M from a depressed $83.6M in FY2024 (which was weighed down by one-time items), with operating income of $466M and EPS of $1.94. The 22.3% operating margin and 20.3% net margin reflect the underlying earnings power once the prior-year charges roll off, and the rebound brings profitability back in line with the company's FY2021-2022 range ($423M-$513M).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $2.14B | $1.97B | $1.98B | $2.09B |
| Gross profit | $1.45B | $1.38B | $1.23B | $967M | $1.30B |
| Operating income | $630M | $531M | $410M | $97.7M | $466M |
| Net income | $513M | $423M | $341M | $83.6M | $425M |
| Diluted EPS | $2.21 | $1.84 | $1.48 | $0.37 | $1.94 |
| Net margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.36B
EV / EBITDA14.2
EV / Sales4.5
EV / FCF20.7
P / FCF18.9
PEG (trailing)0.05
Earnings yield5.0%
FCF yield5.3%
Quality & risk
ROIC (est.)6.8%
Free cash flow$453M
Total debt$1.65B
Net cash-$815M
Piotroski F-Score7/9
Capital returns
Buyback yield3.3%
Dividend yield (est.)0.6%
Shareholder yield3.9%
Shares Δ YoY-2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗SCHEDULE 13G/AFiling2026-06-05open ↗SDFiling2026-06-01open ↗6-KPeriod ending 2026-03-312026-05-08open ↗6-KPeriod ending 2026-03-312026-05-08open ↗6-KPeriod ending 2026-03-312026-05-01open ↗IRANNOTICEFiling2026-03-20open ↗20-FPeriod ending 2025-12-312026-03-20open ↗SCHEDULE 13G/AFiling2026-02-10open ↗SCHEDULE 13GFiling2026-02-06open ↗6-KPeriod ending 2025-12-312026-02-06open ↗25-NSE/AFiling2026-01-09open ↗25-NSEFiling2026-01-08open ↗
Frequently asked
- Is QIAGEN N.V. (QGEN) a buy?
- QGEN currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. High-margin molecular-diagnostics franchise with recovering profitability — net income rebounded sharply on a 62% gross margin.
- What is QGEN's fair value?
- A Modified-Graham model based on QGEN's SEC fundamentals estimates a fair value of about $73.72. It is an estimate from reported earnings, not a price target.
- Is QGEN overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, QGEN currently appears undervalued relative to its SEC-grounded earnings power.
- What is QIAGEN N.V.'s quality score?
- QGEN scores 74.96078431372548/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001015820, latest SCHEDULE 13G/A filed 2026-06-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:04 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.